1Koglin J, Pehlivanli S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure.J Am Coll Cardiol. 2001,38(7) :1934.
2Peter A, McCullough MD, Maisel MD, et al. B - type natriuretic peptides:A diagnostic breakthough for clinicians. Rev Cavdiovasc Med. 2003,4(2) :72.
4Kunii Y, Kamada M, Ohtsuki S, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama. 2003,57(4) :191.
5Koch A, Singer H. Normal value of B type natriuretic peptide in infants,children and adolescents. Heart. 2003,89(8) :875.
6Nit A, Bar - Oz B, Perles Z, et al. N - terminal pro - B - type natriureric peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr. 2004,93(5) :603.
7Storti S, Prontera C, Emdin M, et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic poptide assay: comparison with a point of care testing method. Clin Chem Lab Med. 2004,42(10) :1178.
8Yuk ML, Bradley BK, Brian MF, et al. Usefulness of plasma B - type natriuretic peptide to identify ventricular dysfunction in pediatric and adult patients with congenital heart disease. Cardiosource. 2005,95(4) : 474.
9Koulouri S, Acherman RJ, Wong PC, et al. Utility of B - type natriuretic peptide in differentiating congestive heart failure from lung disease in pediatric patients with respiratory distress. Pediatr Cardiol. 2004,25 (4) :341.
10Cohen S, Springer C, Avital A, et al. Amino - terminal pro-brain-type natriuretic peptide: Heart or lung disease in pediatric respiratory distress? Pediatrics. 2005,115(5) :1347.
